InMed Pharmaceuticals Inc. (INM)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$1.330.00%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $7.3M
- 52-week range
- $0.575 – $2.50
- 52-week change
- −41.15%
- EPS (trailing)
- −$2.84
- Next earnings
- Nov 5, 2026
Fiscal year to Jun 2026
- Net income
- −$12.6M
- Diluted EPS
- −$3.12
From the company’s annual report on SEC EDGAR.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Headquarters: Vancouver, Canada · 6 employees · inmedpharma.com